A randomized, placebo-controlled, double-blind phase 2 study of gemcitabine plus LY293111 [etalocib] compared to gemcitabine plus placebo in patients with locally advanced or metastatic pancreatic cancer

Trial Profile

A randomized, placebo-controlled, double-blind phase 2 study of gemcitabine plus LY293111 [etalocib] compared to gemcitabine plus placebo in patients with locally advanced or metastatic pancreatic cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2009

At a glance

  • Drugs Etalocib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 11 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top